Archives of Head and Neck Surgery
Archives of Head and Neck Surgery
Original Article Thyroid diseases and tumors

The risk of recurrence within the first five years is very low in patients with papillary thyroid carcinoma treated with radioiodine

Pedro Weslley Rosario, Gabriela Franco Mourão Maria Regina Calsolari

Downloads: 1
Views: 363


Introduction: In older studies, the frequency of recurrence was approximately 20% among patients with papillary thyroid carcinoma (PTC) treated with radioactive iodine (RAI), but it is possible that many of these cases actually correspond to persistent disease and that the frequency of recurrence is overestimated. Objective: To reevaluate the frequency of recurrence within the first five years in patients with PTC adequately operated upon and treated with RAI who did not exhibit persistent disease (postoperative ultrasonography and post-therapy whole-body scanning showing no apparent tumor). Methods: We selected 293 patients [51 low risk (17.4%) and 242 intermediate risk (82.6%)] submitted to thyroidectomy followed by RAI who did not have persistent disease. Results: Five years after RAI therapy, a tumor was detected in 10 patients (3.4%) (lymph node metastases in seven, pulmonary metastases in two, and bone metastases in one). Structural recurrence was observed in only 2% of low-risk patients and in 3.3% of intermediate-risk patients, with disease progression in none of the low-risk patients and in only one (0.4%) of the intermediate-risk patients. Survival was 100%. Conclusion: The results of this study suggest that, after adequate total thyroidectomy and in the absence of persistent disease, the frequency of recurrence within the first five years is very low in patients with PTC (not high risk) treated with RAI.


carcinoma; papillary; follicular; ultrasonography; doppler; whole body imaging


1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28. PMid:7977430

2. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723-9. PMid:16030160.

3. Hay ID, Johnson TR, Kaggal S, Reinalda MS, Iniguez-Ariza NM, Grant CS, Pittock ST, Thompson GB. Papillary Thyroid Carcinoma (PTC) in children and adults: comparison of initial presentation and long-term postoperative outcome in 4432 patients consecutively treated at the Mayo Clinic During Eight Decades (1936-2015). World J Surg. 2018;42(2):329-42. PMid:29030676.

4. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-63. PMid:11297567.

5. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, Embia OM, Angelos P, Kaplan EL, Schechter RB. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013;154(6):1436-46, discussion 1446-7. PMid:24075674.

6. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85(1):175-8. PMid:10634383.

7. Rosário PW, Barroso AL, Purisch S. Postoperative uptake in the thyroid bed, not tumor stage, determines the usefulness of diagnostic whole body scan in the first year after ablation with radioiodine. Thyroid. 2007;17(8):803-4. PMid:17708716.

8. Rosário PW, Guimarães VC, Maia FF, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope. 2005;115(2):264-7. mlg.0000154730.31281.0c. PMid:15689747.

9. Lepoutre-Lussey C, Maddah D, Golmard JL, Russ G, Tissier F, Trésallet C, Menegaux F, Aurengo A, Leenhardt L. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol. 2014;170(6):837-46. PMid:24659355.

10. Matrone A, Gambale C, Piaggi P, Viola D, Giani C, Agate L, Bottici V, Bianchi F, Materazzi G, Vitti P, Molinaro E, Elisei R. Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform 131I Ablation. J Clin Endocrinol Metab. 2017;102(3):893-902. PMid:27929713.

11. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. PMid:26462967.

12. Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, Padrão EL, Rezende LL, Barroso AL. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med. 2005;24(10):1385-9. PMid:16179622.

13. Rosario PW, Tavares WC, Borges MA, Santos JB, Calsolari MR. Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study. Endocr Pract. 2014;20(4):293-8. PMid:24246348.

14. Rosario PW, Mourão GF, Siman TL, Calsolari MR. Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: A prospective study. Thyroid. 2015;25(7):769-75. PMid:25763842.

15. Rosario PW, Penna GC, Calsolari MR. Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: is lobectomy sufficient for tumours ≥ 1 cm? Clin Endocrinol. 2014;81(4):630-2. PMid:24350640.

16. Sapuppo G, Tavarelli M, Belfiore A, Vigneri R, Pellegriti G. Time to separate Persistent from Recurrent Differentiated Thyroid Cancer: different conditions with different outcomes. J Clin Endocrinol Metab. 2019;104(2):258-65. PMid:30165559.

17. Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, Russ G. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2(3):147-59. PMid:24847448.

18. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D’Apollo R, Giacomelli L, Ronga G, Filetti S. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98(2):636-42. PMid:23293334.

19. Kim H, Kim TH, Choe JH, Kim JH, Kim JS, Oh YL, Hahn SY, Shin JH, Chi SA, Jung SH, Kim YN, Kim HI, Kim SW, Chung JH. Patterns of Initial Recurrence in Completely Resected Papillary Thyroid Carcinoma. Thyroid. 2017;27(7):908-14. PMid:28446060.

20. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(3):1440-5. PMid:15613412.

21. Rosario PW, Furtado MS, Mourão GF, Calsolari MR. Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to american thyroid association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid. 2015;25(11):1243-8. PMid:26359309.

5dd2d3c00e8825916cc63493 archives Articles
Links & Downloads

Arch. Head Neck Surg.

Share this page
Page Sections